Insider Trading June 17, 2026 07:19 PM

Anterix Executive Offloads $7.5M in Stock Amid Surge

Chief Regulatory & Communications Officer Christopher Guttman-McCabe reports significant sales as ATEX trades near 52-week highs, coinciding with strong Q4 fiscal 2026 earnings.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
ATEX

Christopher Guttman-McCabe, the Chief Regulatory & Communications Officer at Anterix Inc. (NASDAQ: ATEX), disclosed a series of substantial stock transactions on June 15, 2026. The executive executed a dual strategy of selling a significant portion of his holdings while simultaneously exercising stock options to acquire additional shares. These transactions occur against a backdrop of a remarkable 262% year-to-date surge in ATEX stock, which currently trades near its 52-week high of $88.12. The sales activity coincides with the company's recent release of fiscal fourth-quarter 2026 earnings that significantly surpassed Wall Street expectations, highlighting a period of heightened activity and financial performance for the telecommunications and spectrum management firm.

Anterix Executive Offloads $7.5M in Stock Amid Surge
ATEX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Christopher Guttman-McCabe sold 91,437 shares of Anterix stock valued at approximately $7.5 million, while simultaneously acquiring 122,852 shares through option exercises valued at $4.6 million.
  • Anterix reported fiscal Q4 2026 earnings of $0.98 per share, significantly outperforming the anticipated loss of $0.54 per share, with revenue reaching $1.96 million against estimates of $1.47 million.
  • ATEX stock has surged 262% year-to-date, trading near its 52-week high of $88.12, though InvestingPro analysis suggests the stock may be overvalued with overbought conditions.

Christopher Guttman-McCabe, serving as the Chief Regulatory & Communications Officer for Anterix Inc. (NASDAQ: ATEX), has filed disclosures detailing substantial equity transactions on June 15, 2026. The executive's reported activity involves a significant divestment of common stock alongside a concurrent acquisition of shares through option exercises. Specifically, Mr. Guttman-McCabe sold common stock with a total value of approximately $7,539,883. In a parallel transaction, he acquired shares through stock option exercises valued at roughly $4,604,055.

The executive disposed of a total of 91,437 shares of Anterix common stock. These sales were executed at prices ranging between $81.32 and $84.29 per share. The timing of these divestments is notable given the stock's recent performance. ATEX has surged 262% year-to-date and is currently trading near its 52-week high of $88.12. According to InvestingPro analysis, ATEX may appear overvalued at these current levels, with the stock exhibiting overbought conditions. This assessment is one of 14 key ProTips available to subscribers.

Concurrently with the sales, Mr. Guttman-McCabe acquired 122,852 shares of Anterix common stock by exercising stock options. These acquisitions were made at exercise prices ranging from $25.75 to $49.39 per share. All exercised options were fully vested at the time of the transaction. The reported prices for the sales represent weighted averages, with actual transaction prices falling within specified ranges for each block of shares sold.

Following these transactions, Mr. Guttman-McCabe directly holds 77,807 shares of Anterix common stock. This position reflects the net effect of the recent sales and option exercises.

In broader corporate news, Anterix Inc. recently reported its fiscal fourth-quarter 2026 earnings, surpassing Wall Street expectations. The company achieved earnings of $0.98 per share, outperforming the anticipated loss of $0.54 per share. Revenue for the quarter reached $1.96 million, exceeding estimates of $1.47 million. These results were bolstered by spectrum monetization, stronger cash collection, and early success in new products. Analysts had projected lower figures, making this outcome notable. The company’s financial performance has been a focal point for investors, particularly given the unexpected profitability. These recent developments highlight Anterix’s positive trajectory in its financial operations.

Risks

  • InvestingPro analysis indicates ATEX may be overvalued at current levels, exhibiting overbought conditions, which could signal potential volatility or correction in the stock price.
  • The significant year-to-date surge of 262% in ATEX stock may indicate heightened speculative interest, posing risks for investors regarding valuation sustainability.
  • While recent earnings beat expectations, the reliance on spectrum monetization and new product success introduces uncertainty regarding the sustainability of Anterix's financial trajectory.

More from Insider Trading

CoreWeave Executive Goldberg Chen Executes $594K Stock Sale Amid Market Expansion Jun 17, 2026 Kratos Defense Executive Marie Mendoza Executes Stock Sale Under Pre-Arranged Plan Jun 17, 2026 CrowdStrike CEO George Kurtz Executes $1.29 Million Stock Sale Under Pre-Existing Plan Jun 17, 2026 Aeva Technologies CEO Soroush Salehian Dardashti Executes $6.76 Million Stock Sale Jun 17, 2026 Aeva Technologies CTO Mina Rezk Executes $8.6 Million Share Sale Amid Stock Rally Jun 17, 2026